| Titre | | nb de chargement | |
|---|
| popup | | 2 | |
| popup | | 2 | |
| Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025 | | 16 | |
| Transgene présente des données de survie sans récidive à 24 mois sur l'ensemble des patients de la Phase I de l'étude de son vaccin thérapeutique individualisé TG4050 à l'ASCO 2025 | | 529 | |
| Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer | | 2 | |
| Randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer | | 2 | |
| Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts) | | 2 | |
| Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts) | | 2 | |
| Transgene's Combined General Meeting of May 15, 2025 | | 240 | |
| Assemblée Générale Mixte de Transgene du 15 mai 2025 | | 199 | |
| availability of statutory auditors reports | | 2 | |
| Transgene Provides Business and Financial Update for Q1 2025 | | 530 | |
| Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2025 | | 416 | |
| Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025 | | 324 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2025 | | 290 | |
| Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025 | | 330 | |
| Transgene communiquera, dans une présentation orale rapide, de nouvelles données de Phase I du vaccin thérapeutique individualisé TG4050 à l'ASCO 2025 | | 331 | |
| Availability of Transgene's 2024 Universal Registration Document (URD) | | 291 | |
| Mise à disposition du Document d'Enregistrement Universel (DEU) 2024 de Transgene | | 336 | |
| First-Quarter 2025 Financial Results | | 2 | |
| 2024 Half-Year Results | | 2 | |
| Résultats semestriels 2024 | | 2 | |
| Résultats annuels 2024 et perspectives 2025 | | 2 | |
| 2024 Full-year results and 2025 outlook | | 2 | |
| Simone STEINER | | 2 | |
| Simone STEINER | | 2 | |
| Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations | | 430 | |
| Transgene recrute une Directrice des opérations techniques (CTO) pour accélérer le développement de ses innovations | | 334 | |
| Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine - Strong Outlook for 2025 | | 584 | |
| Transgene franchit des étapes clés en 2024, avec la preuve de principe clinique de son vaccin individualisé contre le cancer - Perspectives prometteuses pour 2025 | | 458 | |
| Investor Access Event (Paris) - April 1, 2025 | | 2 | |
| Transgene to Participate in Upcoming Investor Meetings | | 482 | |
| Transgene participera à de prochaines rencontres investisseurs | | 297 | |
| TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment | | 2 | |
| TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment | | 2 | |
| ASCO 2025 | | 3 | |
| ASCO 2025 | | 3 | |
| Investor Access Event - Paris, 1er avril 2025 | | 3 | |
| Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts | | 648 | |
| L'action Transgene (Euronext Paris : TNG) éligible au dispositif du PEA-PME | | 458 | |
| Transgene To Participate in the Biomed Forum Investor Conference | | 517 | |
| Transgene participera à la conférence investisseurs Biomed Forum | | 429 | |
| Transgene Announces Financial Calendar for 2025 | | 730 | |
| Transgene présente son calendrier de communication financière pour 2025 | | 542 | |
| Transgene Reports Business, Pipeline and Financial Update for Q3 2024 | | 1016 | |
| Transgene fait le point sur ses activités, son portefeuille et sa situation financière au troisième trimestre 2024 | | 759 | |
| Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment | | 800 | |
| Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés | | 627 | |
| Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 | | 4 | |
| Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 | | 3230 | |
| Contact-fr | | 4 | |
| menu principal | | 4 | |
| TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery | | 4 | |
| TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery | | 4 | |
| TG4001+Avelumab vs Avelumab Single-Agent Phase II Update | | 4 | |
| TG4001+Avelumab vs Avelumab Single-Agent Phase II Update | | 4 | |
| Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers | | 1331 | |
| Transgene fait le point sur létude de Phase II du vaccin thérapeutique TG4001 dans les cancers du col de lutérus et anogénitaux HPV16 positifs, récurrents ou métastatiques | | 844 | |
| Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC) | | 4 | |
| Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC) | | 4 | |
| Vaccins thérapeutiques à antigènes partagés | | 4 | |
| Vaccins thérapeutiques individualisés | | 4 | |
| Shared antigens cancer vaccines | | 4 | |
| Individualized neoantigen cancer vaccines | | 4 | |
| Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024 | | 946 | |
| Transgene présentera un poster sur les données actualisées de TG4050 au SITC 2024 | | 1069 | |
| Transgene to Report Major Clinical Data before the end of 2024 - Confirmed Financial Visibility until Q4 2025 | | 1303 | |
| Transgene prévoit d'importants résultats cliniques d'ici fin 2024 et confirme sa visibilité financière jusqu'au 4ème trimestre 2024 | | 840 | |
| Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment | | 1281 | |
| Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l'étude en cours de Phase I/IIa dans les tumeurs solides résistantes | | 1805 | |
| Emmanuelle DOCHY, MD | | 4 | |
| Emmanuelle DOCHY, MD | | 4 | |
| Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation | | 846 | |
| Transgene nomme deux experts en oncologie pour conduire sa prochaine phase d'innovation | | 741 | |
| Maurizio CEPPI, PhD | | 4 | |
| Maurizio CEPPI, PhD | | 4 | |
| TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment | | 4 | |
| TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment | | 4 | |
| Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024 | | 796 | |
| Transgene et BioInvent présentent des données cliniques prometteuses de l'essai de Phase I/IIa du virus oncolytique BT-001 à l'ESMO 2024 | | 657 | |
| Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors | | 4 | |
| Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors | | 4 | |
| Transgene to Participate in HTID Conference and Investor Access Forum in Paris | | 826 | |
| Transgene participera au HTID et à l'Investor Access Forum à Paris | | 436 | |
| TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment | | 4 | |
| Transgene Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC | | 912 | |
| Transgene publie dans le JITC des données de preuve de concept préclinique du virus oncolytique TG6050 | | 595 | |
| Transgene annonce la mise à disposition d'un prospectus dans le cadre de la conversion en actions d'une partie de l'avance en compte-courant de TSGH | | 733 | |
| Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH | | 1460 | |
| Transgene renforce son bilan par la conversion en actions dune partie de lavance en compte-courant de TSGH | | 823 | |
| Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024 | | 948 | |
| Transgene et BioInvent présentent un poster sur le virus oncolytique BT-001, à l'ESMO 2024 | | 782 | |
| menu principal | | 16 | |
| Assemblée générale | | 16 | |
| Événements et présentations | | 16 | |
| Information boursière | | 16 | |
| Information financière | | 16 | |
| Investor Events & Presentation | | 16 | |
| Annual General Meeting | | 16 | |
| Stock Information | | 16 | |
| Financial Information | | 16 | |
| menu principal | | 16 | |
| menu principal | | 16 | |
| | 16 | |
| | 16 | |
| menu principal | | 16 | |
| Transgene KOL event TG4050 | | 16 | |
| Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer | | 1701 | |
| Transgene Premier patient inclus dans la partie Phase II de létude randomisée de Phase I/II de son actif phare TG4050 un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou | | 1130 | |
| Michel BAGUENAULT | | 16 | |
| Michel Baguenault | | 16 | |
| Transgene's Combined General Meeting of May 15, 2024 | | 2085 | |
| Assemblée Générale Mixte de Transgene du 15 mai 2024 | | 1305 | |
| Transgene provides business and financial update for Q1 2024 | | 1439 | |
| Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024 | | 1728 | |
| Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024 | | 1681 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024 | | 1410 | |
| Availability of Transgene's 2023 Universal Registration Document | | 1647 | |
| Mise à disposition du document d'enregistrement universel 2023 de Transgene | | 1634 | |
| Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 | | 2505 | |
| Transgene et NEC présentent les premières données cliniques de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à lAACR 2024 | | 1957 | |
| Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers | | 18 | |
| Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers | | 19 | |
| Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 | | 1204 | |
| Transgene prévoit des avancées significatives sur son portefeuille d'immunothérapie en 2024 et étend sa visibilité financière jusqu'au 4ème trimestre 2025 | | 1751 | |
| Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer | | 1529 | |
| Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer comme Directrice des Ressources Humaines | | 2286 | |
| Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 2, 2025 | | 64 | |
| Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands) - 2 avril, 2025 | | 64 | |
| Transgene Announces Upcoming Investor Meetings | | 1201 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 946 | |
| Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024 | | 2437 | |
| Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l'AACR 2024 | | 1579 | |
| Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 | | 1375 | |
| Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l'essai clinique de Phase I/II du vaccin individualisé TG4050 | | 1125 | |
| Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer | | 3155 | |
| Transgene annonce la nomination de James Wentworth comme Directeur du Business Development | | 1516 | |
| Transgene Announces Financial Calendar for 2024 | | 2098 | |
| Transgene présente son calendrier de communication financière pour 2024 | | 1499 | |
| Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050 | | 1766 | |
| Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer | | 5974 | |
| Lucie Larguier | | 88 | |
| Lucie LARGUIER | | 88 | |
| Transgene Announces Upcoming Investor Meetings | | 6208 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 1428 | |
| Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy | | 14342 | |
| Transgene renforce son équipe de direction pour accélérer sa stratégie de croissance | | 2451 | |
| Transgene reports business update and Q3 2023 financial position | | 8858 | |
| Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2023 | | 3762 | |
| Transgene and BioInvent - First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab) | | 15885 | |